Related Experiment Video
Updated: Jan 14, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Non-Cirrhotic Steatotic Liver Disease is Associated With Impaired Muscle Function: A Cross-Sectional Study
Guillaume Henin1,2, Alexis Goffaux1, Salomé Declerck1
1Laboratoire de gastro-entérologie (GAEN) Institut de recherche expérimentale et clinique (IREC), UCLouvain Brussels Belgium.
Background:
Impaired muscle function is frequent in cirrhosis and potentially participates in liver disease progression. Data from non-cirrhotic patients with steatotic liver disease (SLD) are lacking. Our aims were to determine if muscle function was impaired in a non-cirrhotic cohort of patients with SLD and if the SLD subtype and severity were associated with impaired muscle function.
Methods:
Patients with SLD and controls were prospectively recruited. Liver disease was assessed by imaging, vibration-controlled transient elastography and non-invasive tests. Muscle function was assessed by the liver frailty index (LFI) and isokinetic dynamometer. Diet and physical activity habits were recorded using dedicated questionnaires to measure the energetic balance.
Results:
One-hundred and fifty patients with non-cirrhotic SLD (75 patients with metabolic dysfunction-associated steatotic liver disease [MASLD] and 75 patients with alcohol-related liver disease [ALD]) and 30 non-SLD controls were prospectively recruited. The LFI negatively correlated to lower limb muscle strength assessed by isokinetic dynamometer in all participant groups (r = 0.82 in the control group; r = 0.69 in the pooled SLD group-p < 0.0001). Both SLD groups showed muscle strength impairment assessed by the LFI compared to age- and gender-matched controls. In multivariate analysis, the presence of SLD was associated with impaired muscle function independently of age, BMI and energetic balance, with a higher risk related to ALD.
Conclusions:
Patients with SLD already show impaired muscle function compared to controls independently of age, gender and energetic balance. Taken together, our data support a potential disruption of the liver-muscle axis already occurring in SLD prior to cirrhosis.
Trial Registration:
ClinicalTrials.gov identifier: NCT06514300.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Cross-bridge Cycle
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...